Business Daily (BBC World Service)
Episode: The Worldwide Weight-Loss Revolution
Date: March 3, 2026
Host: Sam Fenwick
Overview
This episode—the second in a three-part series on the global weight loss economy—explores who actually pays for new, highly effective obesity drugs worldwide, how different countries’ health systems are coping with the cost, and whether these drugs truly represent value for money. The discussion centers on access, affordability, and the economic impact of the GLP-1 weight loss medications across England, the UAE, and India, highlighting issues of inequality, healthcare policy, and pharmaceutical market dynamics.
Key Discussion Points and Insights
1. The High Cost and Limited Access to Obesity Drugs
- The rise of GLP-1 drugs (like Mounjaro, Wegovy) offers hope for tackling obesity but presents new challenges regarding cost and access.
- Most sales currently benefit upper socioeconomic groups, leading to inequality in treatment access.
"Most of the sales for these drugs currently are accounted for by the upper socio economic strata." — Ashna Mehta [01:47]
2. England's Public Health Dilemma
- NHS England bases drug funding decisions on cost-effectiveness via the National Institute for Health and Care Excellence (NICE), which sets strict eligibility criteria.
- Criteria typically involve BMI and obesity-related health conditions.
- NICE deems the drugs good value for money, not just for weight loss, but for reducing risks of diabetes, stroke, and heart disease.
"For the NHS, for people who successfully lose weight using GLP1s, it will lower their risk of developing those types of conditions, as well as the costs to the NHS of having to treat those conditions in the future." — Jacqueline Bouvet [05:07]
- However, funding is limited—if all eligible patients (around 3.4 million people) accessed the drugs immediately, they'd consume 18% of all primary care resources.
- The NHS is therefore rolling out the drugs very gradually, targeting those most in need (roughly 220,000 people over three years).
Private Market Emerges
- Those excluded from NHS coverage increasingly turn to the private market.
- Example: Claire Barrett, FT journalist, spent £4,000–£4,500 privately over 18 months. She notes the cost gave her extra motivation but acknowledges the resulting inequality.
"I think that's a bargain... I've basically spent around £1,000 for every stone I've lost." — Claire Barrett [08:33]
"Well, it is a luxury for the rich. I make absolutely no bones about that." — Claire Barrett [09:01]
3. The UAE: Private Wealth and Insurance Barriers
- Despite being a wealthy nation, most UAE treatments are through the private sector or employer insurance, which often excludes “lifestyle” treatments like weight-loss drugs.
- Out-of-pocket monthly drug costs range from $800–$1,300 USD.
- Demand is “humongous,” but health insurers resist coverage to avoid “budget bloat,” making access prohibitive for most.
"We are having stiff resistance from the health insurance side because they don't want their budget to bloat." — Prakash Paniya [11:32]
"At the current prices, no, [the healthcare system] can't cope with it." — Prakash Paniya [13:37]
4. India: Rising Need and Hope for Generics
- India faces a rising tide of obesity—one in four adults is overweight or obese, costing the economy $29 billion annually (1% of GDP).
- The vast majority of healthcare expenses are out-of-pocket, as public sector networks can't meet demand.
- Drug prices ($120–$160/month for initial doses) are out of reach for most, so usage is concentrated among the wealthy.
"Most of the sales for these drugs currently are accounted for by the upper socio economic strata within the country." — Ashna Mehta [16:57]
- However, imminent arrival of Indian-made generic GLP-1 drugs is expected to cut prices by up to 70%, potentially broadening access through India’s robust generics industry.
“Prices will be slashed at least by half. Some reports suggest that they may go down by about 70% because India has a very robust generic industry.” — Ashna Mehta [17:35]
5. The Pharma Perspective: Global Self-Pay Market and Price Pressure
- Currently, the majority of the global obesity drugs market is self-pay, and the manufacturers acknowledge the price sensitivity.
“The majority of the obesity market at a global scale is a self pay market. ... We need to find the appropriate price points that balances patient affordability with the value our products are bringing.” — Carsten Knudsen, Novo Nordisk CFO [14:06]
- Patent expiry in India (and soon China) will unleash price competition, with Indian generics already poised to significantly undercut existing brands.
- This opens the door to lower prices globally, but change may remain slow for much of the world due to regulatory and market strategies by existing drug manufacturers.
“In a few international operations markets, there will be a price competition, so we will also be having tactics including launching second brands of Semaglutide at different price points.” — Carsten Knudsen [18:33]
Notable Quotes & Memorable Moments
- On her personal transformation:
“Never before in my life have I sort of caught a glimpse of myself in ... a mirror in a changing room and actually thought that I like what I see.”
— Claire Barrett [03:54] - On NHS rationing and resources:
“If everyone would come forward in the first year of it being available, it would take up, I think, something like 18% of the total primary care services.”
— Jacqueline Bouvet [01:58]/[06:13] - On the societal divide:
“Well, it is a luxury for the rich. I make absolutely no bones about that.”
— Claire Barrett [09:01] - On the Indian generics market:
“Prices will be slashed at least by half. Some reports suggest ... down by about 70% because India has a very robust generic industry.”
— Ashna Mehta [17:35] - On future price competition:
“So we will also be having tactics including launching second brands of Semaglutide at different price points. So we are going also head to head on pricing with their generic entrants.”
— Carsten Knudsen [18:33]
Timeline of Key Segments
- [01:16] Introduction: Framing the episode and what’s at stake globally
- [02:10]–[06:31] How NHS England decides on funding and rationing obesity drugs
- [06:31]–[09:33] Private costs in England and the emergence of inequality
- [10:48]–[13:46] The UAE: Private sector, insurance, and prohibitive costs
- [14:06]–[14:42] Pharmaceutical perspective on pricing and affordability
- [15:20]–[17:09] India: Socio-economic gaps, costs, and the rising prospect of generics
- [17:35]–[19:17] Impact of India’s generics on global pricing and market competition
- [19:17] Looking ahead: The future of the weight-loss economy
Conclusion
The episode reveals a global inequity in weight-loss drug access, with cost barriers persisting even in richer countries and being especially acute in countries with large low-income populations. While public health systems (like the NHS) see the drugs as cost-effective, funding and capacity constraints lead to strict rationing. In private-market dominant countries, high out-of-pocket costs limit usage to the wealthy. The advent of generics, especially from India, may serve as a turning point—forecasting future price drops and improved access worldwide, though this remains to be fully realized.
Next episode preview: How companies beyond the pharma industry—from food makers to gyms—are capitalizing on the new wave of weight-conscious consumers.